The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-05), HCW Biologics's 14-Day RSI is 34.16.
The industry rank for HCW Biologics's 14-Day RSI or its related term are showing as below:
HCWB's 14-Day RSI is ranked better than 91.68% of 1419
companies
in the Biotechnology industry
Industry Median: 50.98
vs HCWB: 34.16
HCW Biologics (NAS:HCWB) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
HCW Biologics 14-Day RSI Related Terms
HCWB vs KAPA, IMNN, MTVA: 14-Day RSI Comparison
For the Biotechnology subindustry, HCW Biologics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where HCW Biologics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a 14-Day RSI of 34.16 as of Jul. 05, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #118 out of 1419 companies in the Biotechnology industry, placing it in the top 8.3%.
Is HCW Biologics' 14-Day RSI too high?
HCW Biologics' current 14-Day RSI is 34.16. The Biotechnology industry median 14-Day RSI is 50.98. HCW Biologics' value of 34.16 is 33% below this industry median. Based on the distribution chart, HCW Biologics ranks #118 out of 1419 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' 14-Day RSI compare to KAPA and IMNN?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #118 out of 1419 companies for 14-Day RSI. This places HCW Biologics in the top 8% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 50.98. HCW Biologics' value of 34.16 is 33% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 50.98, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current 14-Day RSI of 34.16 is 33% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 50.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current 14-Day RSI is 34.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $43.78, compared to a current price of $4.30 — trading 90.2% below its estimated fair value. The current 14-Day RSI is 34.16 and 33% below the Biotechnology industry median of 50.98. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For HCW Biologics (HCWB), the current 14-Day RSI is 34.16 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $4.30 is trading 90.2% below its estimated GF Value™ of $43.78.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
14-Day RSI: 34.16
GF Value™: $43.78 vs. price of $4.30 (90.2% below fair value)
Industry Position: 33% below the Biotechnology median (#118 of 1419)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score
Get the complete analysis for HCWB
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 